Tweets
Some of the great questions in ICI-induced irAE pathophysiology, from the great Andy Cope @KingsCollegeLon
#EULAR2024 @RheumNow https://t.co/aHDqnvhboo
David Liew @drdavidliew ( View Tweet )
1 year 7 months ago
🙏🏻I am so grateful for @RheumNow's coverage of our research about radiomics in AxSpA
⭐️I believe radiomics has potential and hope it will become a thing in Rheumatology
👇🏻Here is my interview with @bella_mehta about POS 0236 which I presented at #EULAR2024
https://t.co/yvD9yCIzQ8
Vincenzo Venerito @vincevenerito ( View Tweet )
1 year 7 months ago
DEFINING OVERALL AND SEX-SPECIFIC BASDAI CUT-OFFS FOR DISEASE ACTIVITY STATES IN AXIAL SPONDYLARTHRITIS – RESULTS FROM THE EUROSPA COLLABORATION - more data to stratify for gender at baseline all future AxSpA trials @RheumNow #EULAR2024 https://t.co/nQwCDOxN8R
Peter Nash @drpnash ( View Tweet )
1 year 7 months ago
#EULAR2024 #scleroderma #recommend’ns @eular_org
#lung #ILD
Divide in to
#prevention vs #Rx
#Immune #suppressive #Rx vs
#antifibrotic
My thoughts -?other Rx as ⬆️MR
Likely all effective early #Rx of skin
Improve Risk of
#progression▶️ILD
@EUSTAR_org @RheumNow https://t.co/4wJyeSEHv3
Links:
Janet Pope @Janetbirdope ( View Tweet )
1 year 7 months ago
EFFICACY AND SAFETY OF IXEKIZUMAB IN CHILDREN WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS AND ENTHESITIS RELATED ARTHRITIS (COSPIRIT-JIA): 16-WEEK RESULTS OF A MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY - IL17 effective & safe in JIA @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 7 months ago
Izokibep Ph2b/3 RCT PsA 340+
Primary endpoint ACR50 wk 16
IZO 160 mg Q2W 43%
IZO 160 mg QW 40%
PBO 15%
Effect early as wk 4
PASI100
IZO Q2W 47%
IZO QW 51%
PBO 12%
Safety profile similar to IL-17i
@RheumNow #EULAR2024 LBA0005 https://t.co/vWRQ1ECrAX
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 7 months ago
ReMonit RCT 240+ axSPA pts
Remote Monitoring & Patient-initiated Care NON INFERIOR Usual care for ASDAS <2.1 over 18mo
No diff between Patient-initiated Care & Remote Monitoring
No diff in disease activity & function
>90% satisfaction in all arms
#EULAR2024 @RheumNow LB0004 https://t.co/mLTS5fLXFN
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 7 months ago
This is critical.
If we're going to try and treat pre-RA, it's all about picking the right patient:
- avoid exposing future non-responders to harm
- modify the course of disease in those who will benefit
Fantastic that @eular_org are addressing this need.
#EULAR2024 @RheumNow https://t.co/9pF33eLbuZ
David Liew @drdavidliew ( View Tweet )
1 year 7 months ago
Scleroderma: the present, and the future.
#EULAR2024 @RheumNow https://t.co/v5vxfmM4i3
David Liew @drdavidliew ( View Tweet )
1 year 7 months ago
Open-label extension of BE MOBILE 2 Ph3 Bimekizumab in r-axSpA
200 pts w/ 2yr radiographic outcome
85.3% non progressors (mSASSS CfB ≤0.5) 92.1% (mSASSS CfB <2)
83.1% had existing structural damage (mSASSS ≥2) at BL
#EULAR2024 @RheumNow Abst LBA0003 https://t.co/DQeiXHDnSF
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 7 months ago
PRO-SPIRIT 1100+ PsA Observational study
IXE i= TNFi and JAKi for improving joint dis activity in IXE higher previous b/tsDMARD & less concomitant csDMARDs
IXE & IL-17Ai = faster improvement cDAPSA than IL-12/23i or IL-23i
Abst LBA0002 #EULAR2024 @RheumNow https://t.co/8DbtCQECNN
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 7 months ago
IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1
Is it safe? looks it, no serious AES, 6mo follow up
Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab
Does it work? will have to wait for Phase 2
Somehow bold knowing TCZ did not work in hand OA
AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM
Links:
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 7 months ago
